Clinical Trials Logo

Glomerulonephritis, IGA clinical trials

View clinical trials related to Glomerulonephritis, IGA.

Filter by:

NCT ID: NCT00870493 Completed - IgA Nephropathy Clinical Trials

Aliskiren for Immunoglobulin A (IgA) Nephropathy

Start date: April 2009
Phase: Phase 3
Study type: Interventional

Immunoglobulin A (IgA) nephropathy is the most common type of primary glomerulonephritis in the world. Current treatment with angiotensin converting enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) is not entirely effective. Aliskiren, a direct renin inhibitor, acts on the rate limiting step of the renin-angiotensin axis. In addition to lowering the blood pressure, recent study in diabetic nephropathy suggests an independent anti-proteinuric effect. The investigators plan to conduct a randomized placebo-control cross-over study to evaluate the safety and efficacy of aliskiren in the treatment of IgA nephropathy. The investigators plan to recruit 57 patients with biopsy-proven IgA nephropathy and persistent proteinuria despite conventional therapy. They will be randomized to aliskiren for 16 weeks or no treatment, followed by cross over to the other arm after a washout period. Proteinuria, albuminuria, renal function, serum and urinary markers will be quantified. This study will explore the potential anti-proteinuric effect of aliskiren in the treatment of IgA nephropathy, which has no specific treatment at present.

NCT ID: NCT00863252 Completed - IGA Nephropathy Clinical Trials

Mycophenolate Mofetil for IgA Nephropathy

Start date: March 2002
Phase: Phase 4
Study type: Interventional

IgA nephropathy (IgAN) is the commonest primary glomerulonephritis worldwide. In Hong Kong, IgAN accounts for approximately 30% of all primary glomerular diseases, and a significant proportion of young patients (< 50 years of age) on dialysis therapy are sufferers of primary IgAN. To date, no specific therapeutic agent has been consistently shown to halt the progression of IgAN to end-stage renal failure, particularly in patients with persistent significant proteinuria and the presence of chronic tubulointerstitial inflammation on kidney biopsy. In recent years, angiotensin-converting enzyme inhibitors (ACEI) have been found capable of significantly reducing proteinuria in some IgAN patients, while others, particularly those with the ACE DD genotype, showed either absent or unsatisfactory response to angiotensin blockade. Mycophenolate mofetil (MMF) is a marketed immunosuppressive drug which acts by releasing mycophenolic acid (MPA) to inhibit the de novo pathway of purine synthesis, and hence is relatively selective for lymphocytes. Apart from being efficacious for the prophylaxis of renal allograft rejection and for the induction of remission in severe lupus nephritis, MMF has been anecdotally reported to avert progression to allograft failure in recurrent IgAN of the transplanted kidney. Data on the clinical efficacy of MMF in the treatment of primary IgAN, however, is lacking. In the current proposal, we aim to study the clinical efficacy of MMF in patients with biopsy-proven IgAN and clinically significant proteinuria despite angiotensin blockade. Patients will be followed up for at least 5 years to track any survival difference between groups.

NCT ID: NCT00862693 Recruiting - Autoimmune Diseases Clinical Trials

Calcitriol in the Treatment of Immunoglobulin A Nephropathy

Start date: March 2009
Phase: Phase 4
Study type: Interventional

Immunoglobulin A (IgA) nephropathy is the common primary glomerulonephritis in the world. Much literature suggests that vitamin D and its analogs have profound effects on immune system function and glomerular mesangial cell proliferation. Therefore, the investigators plan to conduct a randomized clinical study to evaluate the efficacy of Calcitriol in the treatment of IgA nephropathy. Forty patients with biopsy-proven IgA nephropathy will be recruited. They will be randomized to Calcitriol for six months or no treatment. Proteinuria, renal function, serum and urinary inflammatory markers will be monitored. This study will explore the potential anti-proteinuric and anti-inflammatory effects of Calcitriol in the treatment of IgA nephropathy, which has no specific treatment at present.

NCT ID: NCT00856674 Terminated - Proteinuria Clinical Trials

Safety Study of of Intravenous CCL2-LPM in Patients With IgA Nephropathy

Start date: March 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety of several dose levels of CCL2-LPM in patients with IgA Nephropathy who have high levels of protein in the urine.

NCT ID: NCT00793585 Completed - IgA Nephropathy Clinical Trials

A Controlled Study of Uric Acid on the Progression of IgA Nephropathy

Start date: July 2007
Phase: N/A
Study type: Interventional

This prospective, randomized controlled study will evaluate the effect of uric acid on the progression of IgA nephropathy.

NCT ID: NCT00767221 Completed - IGA Nephropathy Clinical Trials

Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study

Start date: October 2005
Phase: Phase 2
Study type: Interventional

The study will investigate the effect of PL-56 on albumin leakage and renal function (glomerular filtration rate) in patients with IgA nephropathy. It will also assess the safety of treatment with PL-56.

NCT ID: NCT00755859 Completed - IGA Nephropathy Clinical Trials

"Steroids and Azathioprine Versus Steroids Alone in IgAN"

Start date: May 1998
Phase: Phase 4
Study type: Interventional

In a previous trial the investigators found that the effect of steroids in IgA nephropathy diminish over time. The difference in renal survival is striking up till the third year, but then remains constant. A six-month course of steroid therapy may be not enough to ensure a stable remission. The investigators hypothesized that a more aggressive treatment may obtain long-term better results. The investigators conducted a randomised controlled trial to assess the utility of low-dose azathioprine added to steroids in adult IgAN patients.

NCT ID: NCT00657059 Completed - IgA Nephropathy Clinical Trials

Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)

Start date: September 2007
Phase: Phase 3
Study type: Interventional

A multi-center, randomized, controlled clinical trial to evaluate the short-term and long-term efficacy and safety of mycophenolate mofetil (MMF) in reducing proteinuria and preserving renal function in patients with IgAN who have pre-treated (and continue to be treated) with angiotensin II receptor blockers (ARB), compared to the corticosteroids.

NCT ID: NCT00599963 Withdrawn - IgA Nephropathy Clinical Trials

Paricalcitol for the Treatment of Immunoglobulin A Nephropathy

Start date: January 2008
Phase: Phase 3
Study type: Interventional

Immunoglobulin A (IgA) nephropathy is the common type of primary glomerulonephritis in the world. A wealth of literature suggests that vitamin D and its analogs have profound effects on immune system function and glomerular mesangial cell proliferation. However, calcitriol, the standard form of vitamin D, carries a substantial risk of hypercalcemia. Recently, paricalcitol (19-nor-1,25-dihydroxyvitamin D2) was approved for the treatment of secondary hyperparathyroidism in chronic renal failure, and the incidence of hypercalcemia is much lower than calcitriol. Therefore, the investigators plan to conduct a randomized cross-over study to evaluate the efficacy of paricalcitol in the treatment of IgA nephropathy. Thirty patients with biopsy-proven IgA nephropathy will be recruited. They will be randomized to paricalcitol for 12 weeks or no treatment, followed by cross over to the other arm after a washout period. Proteinuria, renal function, serum and urinary inflammatory markers will be monitored. This study will explore the potential anti-proteinuric and anti-inflammatory effects of paricalcitol in the treatment of IgA nephropathy, which has no specific treatment at present.

NCT ID: NCT00554502 Completed - IgA Nephropathy Clinical Trials

Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy

STOP-IgAN
Start date: February 2008
Phase: Phase 3
Study type: Interventional

- Evaluation of the efficacy of an immunosuppressive therapy added to a comprehensive supportive therapy to induce a clinical remission in patients at risk for progressive IgAN - Investigation of differences between the treatments regarding the number of patients loosing more than 15 ml/min of GFR.